Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
January 2017
-
Media ReleaseNovartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSCVotubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) Approval addresses unmet…
-
Media ReleaseNovartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance ReportNovartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program Novartis improved position in…
-
Media ReleaseAlcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgeryInnovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
-
Media ReleaseNovartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buybackFY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow…
-
Media ReleaseNovartis: solide performance en 2016, les produits de croissance[1] absorbant la perte d'exclusivité de Gleevec aux USA; dynamique continue d'innovation; rachat d'actions annoncéChiffre d'affaires net de l'exercice 2016 (0% tcc[2]) comparable à celui de l'exercice précédent, grâce à l'excellente performance des produits de croissance Cosentyx (USD 1,1 milliard) a…
-
Media ReleaseNovartis erzielt 2016 solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust der Exklusivrechte für Gleevec in den USA wettmachen; Innovationsdynamik hält an; Aktienrückkauf angekündigtDer Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170…
-
Media ReleaseNovartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disordersNovartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
December 2016
-
Media ReleaseNovartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients…
-
Media ReleaseNovartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseasesNovartis to broaden liver portfolio to deliver best-in-class single and combination therapies for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis through an option,…
-
Media ReleaseNovartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever SyndromesPeriodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
-
Media ReleaseNovartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSCIf approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
Pagination
- ‹ Previous page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- …
- 100
- › Next page